Recent work investigating genomic alterations in a cohort of 893 GBM patient tissues, showed that deletion of NFκB inhibitor, IκBα, is associated with disease progression, tumor recurrence and overall shorter patient survival [57]. Here, NFKB1 is linked to glioblastoma.